Search research articles
Contact Us
Filters
Showing results (101-110 of 192) with videos related to
Page
of 20
Sort By:
Neuroendocrinology
|
August 29, 2018
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Jaume Capdevila, Lisa Bodei, Philippa Davies, et al.
Endocrine-Related Cancer
|
January 9, 2016
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
Future Oncology (London, England)
|
November 3, 2016
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience
Guillermo Crespo, Paula Jiménez-Fonseca, Ana Custodio, et al.
European Thyroid Journal
|
June 20, 2025
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus
Aleš Ryška, Jaume Capdevila, Matthias S Dettmer, et al.
Cancer
|
October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial
Marcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
Molecular Cancer Therapeutics
|
June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Neuroendocrinology
|
July 2, 2025
Smoking Adversely Affects Survival of Metastatic Lung Carcinoid Patients: Analysis of a Large International Audit and Prognostic Models for Metastasis-Free Survival and Overall Survival
Amy Clarke, Aimee Cunningham, Alejandro Garcia-Alvarez, et al.
The Lancet. Oncology
|
July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Molecular Cancer Therapeutics
|
September 22, 2019
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Jaume Capdevila, Ignacio Matos, Francesco M Mancuso, et al.
Anti-Cancer Drugs
|
January 25, 2020
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
Tal Grenader, Marianne E Pavel, Philippe B Ruszniewski, et al.
Page
of 20
Search research articles
Search
Showing results (101-110 of 192) with videos related to
Sort By:
Page
of 20
Neuroendocrinology
|
August 29, 2018
Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
Jaume Capdevila, Lisa Bodei, Philippa Davies, et al.
Endocrine-Related Cancer
|
January 9, 2016
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Martyn E Caplin, Marianne Pavel, Jarosław B Ćwikła, et al.
Future Oncology (London, England)
|
November 3, 2016
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience
Guillermo Crespo, Paula Jiménez-Fonseca, Ana Custodio, et al.
European Thyroid Journal
|
June 20, 2025
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus
Aleš Ryška, Jaume Capdevila, Matthias S Dettmer, et al.
Cancer
|
October 19, 2022
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial
Marcia S Brose, Bruce G Robinson, Steven I Sherman, et al.
Molecular Cancer Therapeutics
|
June 23, 2012
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials
Rodrigo Dienstmann, Danila Serpico, Jordi Rodon, et al.
Neuroendocrinology
|
July 2, 2025
Smoking Adversely Affects Survival of Metastatic Lung Carcinoid Patients: Analysis of a Large International Audit and Prognostic Models for Metastasis-Free Survival and Overall Survival
Amy Clarke, Aimee Cunningham, Alejandro Garcia-Alvarez, et al.
The Lancet. Oncology
|
July 8, 2021
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S Brose, Bruce Robinson, Steven I Sherman, et al.
Molecular Cancer Therapeutics
|
September 22, 2019
Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial
Jaume Capdevila, Ignacio Matos, Francesco M Mancuso, et al.
Anti-Cancer Drugs
|
January 25, 2020
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors
Tal Grenader, Marianne E Pavel, Philippe B Ruszniewski, et al.
Page
of 20